Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of α-synuclein seed amplification assay positivity in remotely followed <i>LRRK2</i> G2019S carriers using a validated data-driven model.

Journal of clinical and translational science·2026
Same author

Reach of Palliative Care in Parkinson Disease: Progress and Gaps After a National Team-Based Implementation Project.

Neurology. Clinical practice·2026
Same author

New onset seizure etiologies and outcomes among adults with HIV in the era of broadly available antiretroviral therapies.

Seizure·2026
Same author

Explore thyself: is it time for metacognition screening in clinical trials?

Clinical parkinsonism & related disorders·2026
Same author

On Multiple Time Scales and Collapsibility.

Lifetime data analysis·2026
Same author

Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.

Journal of neurology·2026

Related Experiment Video

Updated: Jun 18, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Levodopa response in early Parkinson's disease.

Robert A Hauser1, Peggy Auinger, David Oakes

  • 1Department of Neurology, University of South Florida, Tampa, Florida 33606, USA. rhauser@health.usf.edu

Movement Disorders : Official Journal of the Movement Disorder Society
|November 13, 2009
PubMed
Summary

Levodopa significantly improved Parkinson's disease (PD) motor symptoms compared to placebo, but responses varied widely. An improvement of approximately 22% in UPDRS motor scores best distinguished levodopa treatment in early PD.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Early Parkinson's disease (PD) treatment often involves levodopa.
  • Understanding the short-term response to levodopa is crucial for early management.
  • The ELLDOPA study provides data to analyze levodopa's efficacy in early PD.

Purpose of the Study:

  • To characterize the short-term levodopa response in early Parkinson's disease.
  • To identify UPDRS motor score (UPDRSm) changes that best discriminate levodopa from placebo.
  • To explore associations between baseline characteristics and levodopa response magnitude.

Main Methods:

  • Retrospective analysis of the ELLDOPA study data.
  • Evaluation of changes in UPDRS motor scores (UPDRSm) from baseline to 9 and 24 weeks.
  • Linear regression to assess baseline characteristics' impact on UPDRSm changes.

Main Results:

  • Levodopa treatment showed significantly greater UPDRSm improvement than placebo at 9 and 24 weeks (P < 0.001).
  • An UPDRSm improvement of ~22% at 9 and 24 weeks best discriminated levodopa 300 mg/day from placebo.
  • No significant associations were found between baseline characteristics and the magnitude of response.

Conclusions:

  • Levodopa significantly improves motor signs in early PD compared to placebo.
  • There is considerable overlap and wide variability in individual responses to levodopa and placebo.
  • A substantial portion of early PD patients may not exhibit a robust levodopa response.